Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 5/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5024524 | 0.90 | MEN1 (0.52) | OXTRMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL14285167 | 0.85 | ACACB (0.53) | ACACBGAARAB9APPARAPPARG | |
| SCHEMBL14285179 | 0.85 | ACACB (0.53) | ACACBGAARAB9APPARAPPARG | |
| SCHEMBL5027071 | 0.84 | MEN1 (0.51) | OXTRMEN1KMT2APPARAPPARG | |
| SCHEMBL6148806 | 0.83 | MEN1 (0.61) | MEN1KMT2APPARAPPARGPPARD | |
| SCHEMBL5360759 | 0.82 | PPARA (0.49) | OXTRMEN1KMT2APPARAPPARG | |
| SCHEMBL5364857 | 0.81 | PPARA (0.65) | OXTRMEN1KMT2ASMN1; SMN2PPARA | |
| SCHEMBL5028810 | 0.78 | PPARA (0.51) | MEN1KMT2AMAPTSMN1; SMN2PPARA | |
| SCHEMBL14285180 | 0.78 | PPARA (0.51) | MEN1KMT2AMAPTSMN1; SMN2PPARA | |
| SCHEMBL5028808 | 0.78 | PPARA (0.51) | MEN1KMT2AMAPTSMN1; SMN2PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7321056-B2 | Selective peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1697306-B1 | SELECTIVE PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | LILLY CO ELI (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20070066683-A1 | Selective peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066683-A1 | Selective peroxisome proliferator activated receptor modulators | PPARG, PPARD, PPARA | OXTR 1855/4885MEN1 4850/4885KMT2A 3261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.